Clinical Trials Logo

Clinical Trial Summary

The resective-constructive surgery, detailed in prior research by Palacios-Jaraquemada JM, involves excising the placenta and its attachment on the myometrium, with modifications including the systematic use of a double JJ probe, omitting arterial ligation, and prioritizing careful dissection and reconstruction. A prospective single-center study conducted from January 4, 2020, to August 17, 2022, at the Tunisian maternity center included cases of placenta accreta and increta, excluding placenta percreta. Data on operative metrics, complications, transfusions, and ICU admissions were recorded. Diagnosis of placenta accreta spectrum (PAS) relied on imaging and histopathology, with exclusion criteria applied. Surgeons attained proficiency through supervised surgeries. Blood loss calculation incorporated total blood volume and hematocrit changes.


Clinical Trial Description

The surgical procedure known as resective-constructive surgery involves the excision of the placenta and its attachment site on the myometrium. This method has been detailed in prior research by Palacios-Jaraquemada JM, upon which we have built with some modifications. Our modifications include the systematic placement of a double JJ probe under spinal anesthesia, omitting the ligation of hypogastric arteries or uterine arteries. Cesarean sections are performed at 37 weeks of gestational age. We prioritize ligating newly formed blood vessels between the uterus and surrounding structures, carefully dissecting the bladder, performing hysterotomy, and meticulously removing the placenta and its insertion bed until reaching healthy tissues. Subsequently, uterine reconstruction is undertaken. Placental boundaries are identified through extrauterine palpation, followed by a transverse hysterotomy. Intrauterine palpation delineates the inferior margins of the placenta, guiding the resection of the placental bed. Closure is achieved through hysterorrhaphy. Placenta percreta is not addressed in this procedure. The JJ probe is removed post-surgery, and hemostasis is ensured through the modified B-Lynch suturing technique. Postoperative bladder assessment is conducted using a physiological serum. The prospective single-center study spanned from January 4, 2020, to August 17, 2022, encompassing the maternity and neonatology center in Tunis. Placentas diagnosed with accreta and increta were included, while cases of placenta percreta were excluded. Data pertaining to operative time, blood loss, operative complications (such as organ or vessel injury), and postoperative complications (both early and late) were documented. Additionally, the success of the technique, units of blood transfusion administered, and admissions to the intensive care unit (ICU) were meticulously recorded. Suspicion of placenta accreta was initially raised through pelvic MRI and ultrasonography. PAS was confirmed in all enrolled patients based on clinical history, image analysis (including ultrasound, Doppler, and MRI), and histopathological confirmation. Patients lacking an intrasurgical or histopathological diagnosis of PAS were excluded from the statistical analysis. Proficiency in the surgical technique, incorporating specialized hemostasis and dissection maneuvers, was attained by senior obstetricians who participated in 5-7 surgeries before independently managing cases. This approach aimed to ensure the initial reproducibility of the methodology. The calculation of blood loss took into consideration the total blood volume (TBV), pre-partum hematocrit, and post-partum hematocrit, using the following formulas : - Total Calculated Blood Loss (in milliliters of red blood cells) = Total blood volume * Percentage of blood loss - Total Blood Volume = 0.75 x {[height (in inches) x 50] + [weight (in pounds) x 25]} - Percentage of Blood Loss = (pre-partum hematocrit - post-partum hematocrit) / pre-partum hematocrit. This approach ensured accurate assessment of blood loss during the procedures. Sample Size: In determining the sample size for our study, we employed a statistical formula applicable in the context of comparing mean values across two distinct groups, namely the experimental and control groups. This calculation is rooted in the t-test for independent samples. The process entails the following critical steps: 1. Establishing the Significance Level (Alpha): Set at 0.05 to ensure 95% confidence. 2. Selecting the Study's Power (1 - Beta): Predetermined at 90%. 3. Assessing the Standard Deviations of Both Groups: Derived from pilot study data. 4. Identifying the Minimum Clinically Significant Difference (Delta): This represents the smallest difference we aim to detect in our study. Pilot Study: Initially, a pilot study was conducted to ascertain the standard deviations of the two groups and to gain an insight into the expected minimum difference. Main Study: Post-pilot study, we estimated the sample size. The "conservative surgical treatment" group was compared with two "hysterectomy" groups, sharing similar characteristics. Description of Surgical Technique: Our team has formulated illustrative diagrams of the employed surgical method. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06253832
Study type Observational
Source Tunis University
Contact
Status Completed
Phase
Start date January 4, 2020
Completion date January 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT04579172 - Conservative Management of Morbidly Adherent Anterior Situated Placenta N/A
Completed NCT04593303 - Internal Iliac Artery Ligation During Management of Placenta Accreta Spectrum N/A
Recruiting NCT03638024 - Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Not yet recruiting NCT06100640 - Paracervical Pouch in Placenta Accreta Spectrum
Completed NCT05979181 - Peripartum Cesarean Hysterectomy for Placenta Percreta
Recruiting NCT04609527 - Management of Placenta Accreta Spectrum Phase 2/Phase 3
Recruiting NCT06185894 - Single-step Placenta Accreta Resective Technique Tourniqueted vs Absence, Conservative Uterine Surgery N/A
Completed NCT04573452 - Galectin-3 and Placenta Accreta
Not yet recruiting NCT03273569 - PDIUC Protocol for Placental Accreta N/A
Completed NCT03707132 - Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
Not yet recruiting NCT05104177 - Effectivness of Conservative Techniques in Management of PAS
Completed NCT02806024 - Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study Phase 4
Active, not recruiting NCT02784886 - Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta N/A
Recruiting NCT05070689 - Placenta Accreta Spectrum Disorders: A. Chohan Continuous Squeezing Suture (ACCSS) N/A
Completed NCT05813743 - Detection of Urinary Bladder Wall Involvement in Abnormally Invasive Placenta (AIP) by 3D Ultrasonography N/A
Withdrawn NCT04003428 - Feasibility of HIFU for Management of Placenta Accreta (HIFU-ACCRETA) N/A
Completed NCT04161521 - Conservative Surgical Novel Technique of Placenta Accreta in Menoufia University Hospital N/A
Recruiting NCT05139498 - Conservative Management for PAS Pilot N/A
Not yet recruiting NCT03530475 - Diagnostic Accuracy of Doppler Ultrasound and Role of Uterine Artery Doppler N/A
Recruiting NCT05922397 - Placenta Accreta Spectrum Topographic Classification